|
Match
|
Document |
Document Title |
|
|
6413520 |
Methods of immunizing adults using anti-meningococcal vaccine compositions
A method for boosting an immune response against meningococcal capsular antigen is disclosed. The method entails administering a first glycoconjugate vaccine composition to a subject to provide an...
|
|
|
6413510 |
Dimeric modified groβ protein
The invention relates to the method of preventing and treating sepsis using chemokines selected from mature or modified KC [SEQ ID NO: 1], groα[SEQ ID NO:2], groβ[SEQ ID NO: 3] or groγ[SEQ ID...
|
|
|
6413936 |
Glycomimetics as selectin antagonists and pharmaceuticals having antiinflammatory activity
The invention relates to novel mimetics of the tetrasaccharides sialyl-Lewis-X and sialyl-Lewis-A having an improved action as inhibitors of cell adhesion, to a process for the preparation of these...
|
|
|
6410008 |
Chimeric IL-10 proteins and uses thereof
Disclosed are chimeric proteins having IL-10 fused to an enzymatically inactive polypeptide which increases the circulating half-life of IL-10. The chimeric polypeptides are useful for treating or...
|
|
|
6406698 |
Pharmaceutical composition comprising serum amyloid P component for prophylactic or therapeutic treatment of virus infections and a kit for detecting binding of compositions to virus components
Pharmaceutical compositions comprising a protein serum amyloid P component (SAP) capable of binding viruses, especially myxovirus, e.g. influenza viruses and thereby preventing the transmission and...
|
|
|
6406688 |
Method of treating sepsis and ARDS with chemokine β-4
The invention relates to the method of preventing and treating sepsis and ARDS using chemokine β-4 or a biologically active fragment thereof, alone or in conjunction with an anti-infective agent.
|
|
|
6407068 |
Method of treating humans with diseases characterized by high secretion of cytokines from macrophage cells
A method of treating an individual who is suffering from human immunodeficiency virus infection is disclosed. Methods of treating a human suffering from a disease characterized by high secretion of...
|
|
|
6403096 |
Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
A novel permeability enhancing peptide (PEP) is a fragment of interleukin-2. When joined to a delivery vehicle that can target a tumor site, the PEP can increase the subsequent uptake of...
|
|
|
6403078 |
Method and compositions for treating preterm labor and premature rupture of fetal membranes
Methods and compositions for the prevention and treatment of preterm labor and premature rupture of fetal membranes are provided. The methods of the invention inhibit the upregulated production of...
|
|
|
6403077 |
Treatment regimes featuring an IL-10-containing chimeric polypeptide
Disclosed are chimeric proteins having a cytokine fused to an enzymatically inactive polypeptide which increases the circulating half-life of the cytokine. The chimeric proteins are useful for...
|
|
|
6403554 |
Polyunsaturated fatty acid derivatives and their use
Novel amides are disclosed, in particular amides of the all-trans-retinoic acid or 13-cis-retinoic acid and arachidonic acid and docosahexaenoic acid and eicosapentaenoic acid or linoleic acid with...
|
|
|
6399577 |
Compositions and methods using myelin-associated glycoprotein (MAG) and inhibitors thereof
This invention relates to the novel identification of myelin-associated glycoprotein (“MAG”) as a potent inhibitor of neural regeneration. More particularly, this invention relates to...
|
|
|
6399565 |
Therapeutic use of 20-kilodalton human growth hormone
Administration of an administrative amount of an authentic human growth hormone having a molecular weight of 20,000 daltons to human adults can improve body composition, stimulate lipolysis,...
|
|
|
6395268 |
Lymphotactin uses
This invention relates to the use of lymphotactin or lymphotactin antagonists for administration to an animal. The administration of these therapeutic entities will attract certain cell types, or...
|
|
|
6391857 |
Methods and compositions for endothelial binding
Novel methods and compositions are provided for modulating homing of leukocytes, particularly lympho-cytes, where the compounds are cross-reactive with Neu5Ac2-3Galβ1-X[Fucα1-y]GlcNAc, where one...
|
|
|
6391851 |
Hydrochlorides of vancomycin antibiotics and process for producing the same
Process for producing a hydrochloride of a vancomycin antibiotic, comprising subjecting an aqueous solution of a hydrochloride of a vancomycin antibiotic to a primary freezing at from −1° C. to...
|
|
|
6387875 |
Method of use for murine leukaemia inhibitory factor-binding protein (mLBP)
The present invention relates to a isolated leukaemia inhibitory factor (LIF)-binding protein (LBP) in soluble form and obtainable from a first mammalian species, said LBP capable of inhibiting the...
|
|
|
6387884 |
Leukocyte homing modulation
Novel methods and compositions are provided for modulating homing of leukocytes, particularly lymphocytes, where the compounds are cross-reactive with Neu5Ac2-3Galβ1−X[Fucα1−y]GlcNAc, where...
|
|
|
6379684 |
Cosmetic compositions containing cromolyn compounds for revitalizing the skin
Cosmetic compositions and methods are provided for revitalizing the skin especially where it is placed in an environment that can cause injury to the skin. The compositions contain an effective...
|
|
|
6380165 |
Immunological advanced glycation endproduct crosslink
There is disclosed a means for standardizing a kit that provides a means for measuring the formation of advanced glycosylation endproducts (AGEs). The present invention further provides a novel...
|
|
|
6379678 |
Antigenic preparations
The present invention relates to antigenic preparations comprising polysaccharides and/or glycopeptides preparable from keratinophilic fungi as well as yeasts, processes for the preparation of...
|
|
|
6380157 |
Method of treatment using papillomavirus L2 protein
The L2 protein of papillomavirus (particularly BPV-2 and BPV-4) has been cloned as a fusion protein with beta-galactosidase and GST; both as the whole protein and as fragments. Vaccination of...
|
|
|
6376557 |
Methods for treating alopecia
Methods and compositions for the treatment of alopecia and the transdermal delivery of hair growth promoting agents. The compositions are formulated to be applied topically, preferably in the form...
|
|
|
6375950 |
Methods for inducing T cell unresponsiveness to donor tissue or organ in a recipient with gp39 antagonists
Methods for inducing T cell tolerance to a tissue or organ graft in a transplant recipeint are disclosed. The methods involve administering to a subject: 1) an allogeneic or xenogeneic cell which...
|
|
|
6375944 |
Methods and compositions for enhancing the immunostimulatory effect of interleukin-12
Methods for enhancing the therapeutic and adjuvant use of IL-12 by reducing unwanted transient immunosuppression caused by IL-12 or by high doses thereof involve co-administering IL-12 with an...
|
|
|
6372716 |
Formulations for factor IX
Provided by the present invention are novel compositions and methods for obtaining concentrated preparations of factor IX and formulations of factor IX suitable for storage and administration.
|
|
|
6372456 |
Polynucleotides encoding chemokine α-6
The present invention relates to a novel CK(α-6 protein which is a member of the alpha chemokine family. In particular, isolated nucleic acid molecules are provided encoding the human CKα-6...
|
|
|
6368619 |
Hydrophobic preparations of hydrophilic species and process for their preparation
Single phase preparations of hydrophilic species, in particular macromolecular compounds such as proteins or glycoproteins in a hydrophobic solvent such as an oil can be obtained by preparing a...
|
|
|
6365570 |
Pharmaceutical and diagnostic use of Serum Amyloid P component
The invention relates to the new use of Serum Amyloid P component (SAP) and/or endotoxin-binding fragments thereof for the preparation of a pharmaceutical composition for neutralizing...
|
|
|
6361779 |
Transferrin receptor genes
Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic...
|
|
|
6362160 |
Immunophilin-binding agents prevent glutamate neurotoxicity associated with vascular stroke and neurodegenerative diseases
Immunophilin-binding agents inhibit the phosphatase calcineurin, leading to the increased phosphorylation of certain brain proteins, including nitric oxide synthase. The increased levels of...
|
|
|
6358919 |
Polymer compounds comprising glycosphingosine
A polymer compound or a salt thereof which comprises a biodegradable polymer such as polyglutamic acid acetylated at N-terminal thereof containing a glycosphingolipid such as lysoganglioside GM 3 ,...
|
|
|
6358697 |
Intracellular pharmaceutical targeting
A method and composition to target compounds into cells such as eosinophils. A ligand for a CCR-3 eosinophil surface receptor is provided under conditions to bind to the receptor and cause...
|
|
|
6355612 |
Protein material for slow digestion and its use
The subject of the invention is the use of a protein material whose rate of digestion has been reduced, for the preparation of an enteral composition which makes it possible to modulate the...
|
|
|
6355611 |
Salt form of a conjugate useful in the treatment of prostate cancer
The present invention is directed to the sodium salt of formula 5: which may be useful in the treatment of prostate cancer and benign prostatic hyperplasia. Also described are lyophilized...
|
|
|
6352723 |
Brain-derived alkali-soluble immunoregulatory composition
The current invention relates to an active factor present in homogenized brain tissue which inhibits antigen-driven proliferation of lymphocytes in culture, but stimulates proliferation in response...
|
|
|
6350730 |
OB polypeptides and modified forms as modulators of body weight
The present invention relates generally to the control of body weight of animals including mammals and humans, and more particularly to materials identified herein as modulators of body weight, and...
|
|
|
6348191 |
Production and use of IL-6
IL-6 is produced via recombinant DNA techniques. The peptide is useful in the treatment of disorders characterized by deficiencies in hematopoietic cells and in combination with other...
|
|
|
6346513 |
Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
Novel polypeptides having Factor VIII activity are provided as well as compositions and methods for their preparation. The polypeptides comprise derivatives and fragments of Factor VIII and have...
|
|
|
6340783 |
Rodent models of human amyloidoses
In vivo assays for selecting candidate therapeutics for inhibiting amyloidoses, such as congophilic and fibrillar β/A4 amyloid deposition in brain. A candidate reagent is administered to a first...
|
|
|
6338844 |
Genomic nucleic acids, cDNA and mRNA which code for polypeptides with IL-16 activity, processes for the production thereof and their use
A nucleic acid with which expression of a polypeptide having interleukin-16 activity can be achieved or regulated in a prokaryotic or eukaryotic host cell, wherein in the region coding for the...
|
|
|
6337318 |
Sustained GnRH peptide-release formulation
A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15% (w/w) of at least one peptide agonist or analogue other than deslorelin...
|
|
|
6333304 |
Therapeutic compositions containing glucosamine, collagen and a bioflavanol for repair and maintenance of connective tissue
A composition for treating arthroses in animals includes exogenous glucosamine, hydrolyzed collagen and a bioflavanol. Preferred glucosamines are glucosamine hydrochloride (HCI) and glucosamine...
|
|
|
6333034 |
Process for inhibiting complement activation via the alternative pathway
A process of inhibiting activation of complement via the alternative pathway, including inhibiting the formation of complement activation products via the alternative pathway, is provided.
|
|
|
6333306 |
Pharmaceutical combination preparations containing erythropoietin and iron preparations
The present invention is directed to a pharmaceutical combination preparation comprising 2,000-7,000 U of recombinant human erythropoietin (EPO) and 5-20 mg of an Fe(III) complex, wherein the rhEPO...
|
|
|
6326004 |
Antiviral methods using fragments of human rhinovirus receptor (ICAM-1)
Antiviral methods comprising contacting human rhinovirus with tICAM(453).
|
|
|
6323177 |
Interaction of reelin with very low density lipoprotein (VLDL) receptor for screening and therapies
Interaction between Reelin and the very low density lipoprotein (VLDL) receptor has been discovered. This allows development of a convenient assay system for receptor binding that is adaptable for...
|
|
|
6323178 |
Beta-lipotropin methods
The invention provides isolated nucleic acids, vectors, transformed host cells, analogs, functional fragments, and fusion proteins, related to beta-lipotropin. Also provided are pharmaceutical...
|
|
|
6322779 |
Recombinant human CSF-1 dimer and compositions thereof
The present invention is directed to an isolated and purified, recombinant, unglycosylated and dimeric CSF-1, the dimeric CSF-1 being biologically active and essentially endotoxin and pyrogen-free,...
|
|
|
6319896 |
Method of solubilizing, purifying, and refolding protein
A method of modifying protein solubility employs polyionic polymers. These facilitate the solubilization, formulation, purification and refolding of proteins especially incorrectly folded proteins...
|